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a  b  s  t  r  a  c  t
Pigs  play  a  signiﬁcant  role  during  outbreaks  of  foot-and-mouth  disease  (FMD)  due  to  their  ability  to
amplify  the  virus.  It is  therefore  essential  to determine  what  role  vaccination  could  play  to prevent  clinical
disease  and  lower  virus  excretion  into  the  environment.  In this  study  we  investigated  the  efﬁcacy  of  the
double  oil  emulsion  A  Malaysia  97 vaccine  (>6PD50/dose)  against  heterologous  challenge  with an  isolate
belonging  to the  A SEA-97  lineage  at 4 and  7 days  post  vaccination  (dpv).  In  addition,  we  determined
whether physical  separation  of  pigs  in  the  same room  could  prevent  virus  transmission.  Statistically  there
was no difference  in  the  level  of  protection  offered  by  4 and  7  dpv.  However,  no  clinical  disease  or  viral
RNA  was  detected  in  the  blood  of  pigs  challenged  4 dpv,  although  three  of the  pigs had antibodies  to  the
non-structural  proteins  (NSPs),  indicating  viral  replication.  Viral  RNA  was  also  detected  in  nasal  and  saliva
swabs,  but  on  very  few  occasions.  Two  of  the  pigs  vaccinated  seven  days  prior  to  challenge  had  vesicles
distal  from  the injection  site,  but on  the  inoculated  foot, and  two  pigs  had viral  RNA  detected  in the
blood.  One  pig  sero-converted  to the  NSPs.  In  contrast,  all unvaccinated  and  inoculated  pigs  had  evidence
of  infection.  No  infection  occurred  in  any  of  the  susceptible  pigs  in the same  room,  but  separated  from
the  infected  pigs,  indicating  that  strict  biosecurity  measures  were  sufﬁcient  under  these  experimental
conditions  to  prevent  virus  transmission.  However,  viral  RNA  was  detected  in  the  nasal  swabs  of  one  group
of pigs,  but  apparently  not  at sufﬁcient  levels  to  cause  clinical  disease.  Vaccination  led to  a  signiﬁcant
decrease  in  viral  RNA  in  vaccinated  pigs  compared  to  unvaccinated  and  infected  pigs, even  with  this
heterologous  challenge,  and  could  therefore  be considered  as  a control  option  during  outbreaks.
ublis© 2015  The  Authors.  P
. Introduction
Foot-and-mouth disease (FMD) directly impacts livestock pro-
uction due to loss in productivity and usually affects the economy
urther due to quarantine and import restrictions on live animals
nd their products. Vaccination has been used successfully in a
umber of previously endemic countries to control the disease and
∗ Corresponding author. Tel.: +61 03 52275015.
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/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
most countries free from FMD  will consider emergency vaccination
if an outbreak should occur.
Susceptible domestic species include cattle, sheep, goats, pigs
and water buffalo. All may  demonstrate lesions on areas of friction
such as the mouth, feet and teats in lactating animals, but sub-
clinical infections can also occur, especially in sheep and goats [1].
Pigs are the ampliﬁer hosts of the disease and excrete large amounts
of virus in all secretions and excretions [2,3]. For this reason it is
imperative to prevent them from becoming infected or to decrease
viral shedding using vaccination.
There are seven serotypes of FMD  virus (FMDV—A, O, C, Asia-
1, SAT 1, SAT 2 and SAT 3) and large numbers of variants exist
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ithin each. Since cross protection between serotypes does not
xist [4,5], vaccines need to contain multiple strains to ensure
mmunity to more than one serotype. Even within serotypes, pro-
ection is not complete [6,7]. FMDV serotype A viruses have always
een considered to be antigenically the most diverse [8,9], and have
enetically been classiﬁed under three broad genotypes [10]. The
sian genotype consists of several lineages and sub-lineages with
iruses belonging to the lineage A SEA-97 being endemic to South
ast Asia (SEA) and new clusters emerging in the region [10,11].
hese viruses have recently spread beyond the SEA region to cause
utbreaks in countries that were previously free of serotype A [12].
FMD  is endemic in many parts of the world and occurs in
ost countries in SEA. Through their proximity and the amount
f trade and travel, these countries pose the biggest perceived
isk to Australia’s livestock industries and agricultural economy.
ustralia’s last suspected outbreak was in 1872 [13] and having
MD-free status, together with the absence of several other dis-
ases, has provided the country with a signiﬁcant trade advantage.
he local pork industry is small compared to high producing coun-
ries such as China, South Korea and Japan, but the potential overall
osses due to a large outbreak of FMD  could reach 50 billion Aus-
ralian dollars over a 10 year period [14]. For this reason it is
mportant to determine whether the strains in the Australian vac-
ine bank will provide early protection in pigs against the serotype
 viruses that are currently circulating in SEA.
. Materials and methods
.1. Cell lines, viruses and vaccine
Baby hamster kidney-21 (BHK-21) cells were used for all
irus culture. The challenge virus (A/VIT/08/2005) belongs
o the FMDV A SEA-97 topotype, circulating in Vietnam and
ther SEA countries, and has a relative homology (r1) of
.51 to the A Malaysia 97 (A/MAY/97) vaccine strain (WRL
eport 2006; http://www.wrlfmd.org/ref labs/ref lab reports/
IE-FAO%20FMD%20Ref%20Lab%20Network%20Report%202006.
df). The virus was passaged three times in BHK-21 cells before
reparation of the pig-derived challenge virus.
A monovalent double oil emulsion A/MAY/97 vaccine
>6PD50/dose) was prepared by Merial, United Kingdom.
.2. Animal ethics and pigs used in the study
The animal studies were performed according to the Australian
ode of practice for the care and use of animals for scientiﬁc
urposes (AEC1514 and 1571). Sero-negative three-month-old
ross-bred Landrace pigs were obtained from a commercial piggery
n Vietnam.
.3. Preparation of challenge virus
Five healthy pigs were used to prepare pig-derived challenge
irus. Two pigs were administered 1 ml  of A/VIT/08/2005 intra-
enously into the ear vein, 1 ml  intramuscularly on the dorsal aspect
ust behind the left ear and 2 ml  intradermally into the foot-pad of
he left-hind limb at multiple sites (0.1 ml/site in each digit). The
nimals were monitored for the appearance of lesions for three
ays. A 10% (w/v) suspension of tissue homogenate was prepared
n phosphate buffered saline using the epithelial tissue from the
oronary band and foot lesions and three more pigs were inoc-
lated intradermally with 0.1–0.2 ml  of a 10% (w/v) suspension in
he foot pad of the left-fore limb. Epithelial tissue from the coronary
and and foot lesions was collected and a 10% (w/v) suspension of
issue homogenate was prepared and stored at −80 ◦C.ine 33 (2015) 4513–4519
2.4. Titration of A/VIT/08/2005 pig-derived virus
Four healthy pigs were used for titrating the pig-derived virus
at log10 dilutions (10−1 to 10−8) in basal medium eagles (BME) cell
culture medium supplemented with 1% foetal calf serum (FCS). Two
pigs received 0.1–0.2 ml  of inoculum dilutions −2, −3, −4 and −5,
whereas two  other pigs were administered dilutions −4, −5, −6
and −7, intradermally in the footpad. Each dilution was  admin-
istered to two feet. Lesions at the inoculation sites were scored
at 24, 36, 48, 60 and 72 h post inoculation. The 50% pig infective
dose per ml  (PID50/ml) was calculated using the Spearman-Kärber
method [15].
2.5. Pig immunisation and challenge
The experiment consisted of three groups of eight pigs each in
separate rooms. One group was  vaccinated intramuscularly in the
mid  neck region with 2 ml  of vaccine (0.82 mm × 38.1 mm)  seven
days prior to challenge (A-V7), another four days before challenge
(A-V4) and the last group was  left unvaccinated and was challenged
on day 0 (A-UV). Vaccinations were staggered so that the virus
challenge occurred on the same day. For each of these groups, ﬁve
additional non-vaccinated pigs were kept in the same room (com-
prising groups A-UVC7, A-UVC4 and A-UVC), but were separated
by a waist-high steel wall that prevented direct contact with the
challenged animals.
Groups A-V7, A-V4 and A-UV were challenged with 105.0 PID50
of the pig-derived virus by inoculation in two  sites in the left-hind
foot pad (0.2 ml/site). The animals were observed and sampled daily
for 14 days, and rectal temperatures recorded. Clinical scores were
determined by giving each site of lesion development, except the
inoculation site, one point (four feet, tongue, mouth and snout); the
maximum score was  therefore seven. Nasal secretions, saliva and
faeces were collected in duplicate using cotton swabs (diameter:
2.7 mm;  length: 150 mm); one swab was  used for virus isolation
(0.5 ml  of BME  with 10% FCS and antibiotics) and the other for
viral genome detection (0.5 ml  of lysis buffer with carrier RNA and
proteinase K; Startec Biomedical AG, Germany). Swabs were sub-
mersed in the buffer and stored at −80 ◦C. Clotted blood for serum
was collected on −7, −4, 0, 5, 7, 10 and 14 days post-challenge (dpc).
Whole blood was collected in EDTA tubes on 0, 1–7, 9, 10 and 14
dpc.
The animals in groups A-UVC7, A-UVC4 and A-UVC were
observed and sampled as described above. Clotted blood for serum
was collected on days 0, 5, 7, 10 and 14 dpc. Whole blood was
collected in EDTA tubes on 0, 3, 5, 7, 9, 10 and 14 dpc.
2.6. Quantitative real-time reverse transcriptase PCR (RT-qPCR)
for detection of FMD viral RNA
Total RNA from samples was extracted using the InviMag Virus
RNA Mini kit/KF96 (Stratec Molecular, Germany) on an automated
nucleic acid extraction system (KingFisher Flex Magnetic Particle
Processor, ThermoFisher Scientiﬁc, USA) following the manufac-
turer’s protocol. RT-qPCR was carried out using Ambion AgPath-ID
MasterMix (Life Technologies, USA) using the assay previously
described by [16].
In vitro transcribed RNA was prepared using the Megascript
T7 kit (Ambion, USA) from a pBluescript KS+ plasmid containing
the FMDV IRES region [17]. The RNA was puriﬁed and checked
for integrity by RT-PCR using the speciﬁc primers that would
be used for the RT-qPCR [18], and by sequencing. RNA stan-
dards were prepared to determine a standard curve for each
RT-qPCR run.
 / Vacc
2
d
A
d
c
t
1
2
p
p
p
t
t
w
c
2
i
A
s
S
n
f
a
u
q
t
n
s
i
T
S

TS.B. Nagendrakumar et al.
.7. Serology to detect antibodies to FMDV structural proteins
A liquid phase blocking ELISA (LPBE) was  performed as
escribed by Hamblin et al. [19] using A/MAY/97-speciﬁc reagents.
ntibody titres were expressed as the 50% end-point titre, i.e. the
ilution at which the reaction of the test sera resulted in an opti-
al density equal to 50% inhibition of the mean optical density of
he reaction (antigen) control wells [15]. Sera showing a titre of log
.20 were considered positive.
.8. Serology to detect antibodies to FMDV non-structural
roteins
A competitive ELISA (c-ELISA) was performed on serum sam-
les at 1:5 dilutions [20]. The ﬁnal OD values were expressed as
ercentage inhibition relative to the mean OD of the OD Max  con-
rol wells representing the no serum controls i.e. 100 − (100 × (OD
est serum mean/OD Max  control mean)) where a positive result
as recorded for samples that were ≥50% inhibition of the OD max
ontrol.
.9. Statistical analysis
Quantitative data were assessed for normality by calculat-
ng descriptive statistics, plotting histograms, and performing the
nderson–Darling test for normality using commercially available
oftware (MINITAB Statistical Software, Release 13.32, Minitab Inc,
tate College, Pennsylvania, USA). Data were transformed using the
atural logarithm when necessary to improve the distributional
orm prior to statistical analysis. Data were descriptively presented
s the median and range. A linear mixed models approach was
sed to estimate the effect of treatment group on viral genome
uantity determined using RT-qPCR. Independent models were ﬁt-
ed for the four types of PCR specimen (whole blood and oral,
asal, and faecal swabs) in addition to a combined analysis of all
ample types. All models included a random effect term for pig
dentiﬁcation to account for the repeated measurements and also
able 1
ummary of the clinical outcome in pigs after challenge with A/VIT/08/2005. The in-cont
Group Animal ID 1 dpc 2 dpc 3 dpc 4 dpc 
A-UV 1 –  6 6 
2  – 4 4 4 
3  – – 3 4 
4  – 2 2 2 
5   4 4 6 
6  – 4 4 6 
7  – – – 6 
8  – – – – 
A-V4  14 – – – – 
15  –    
16  – – – – 
17  – – – – 
18  –    
19  – – – – 
20  – – – – 
21  –    
A-V7  27 – – – – 
28  – – – – 
29  –    
30  – – – – 
31  –    
32  – – – – 
33  – – – – 
34  – – – – 
 Inoculation site positive; Clinical score was  determined as follows: 1 for each affected
he  maximum score is therefore 7; shaded boxes indicate temp ≥40 ◦C.
a All pigs were euthanized.ine 33 (2015) 4513–4519 4515
included ﬁxed effect terms for treatment group, and experimental
day. Bonferroni correction was used to adjust P values for multi-
ple post-hoc comparisons. Statistical analyses were performed in
commercially available software (IBM SPSS Statistics Version 22,
International Business Machines Corp., Armonk, New York, USA)
and results interpreted at the 5% level of signiﬁcance.
3. Results
3.1. Adaptation and titration of A/VIT/08/2005 in pigs
The challenge virus was passed through pigs twice and had a
titre of approximately 106 PID50/ml  when titrated in pigs.
3.2. Vaccine efﬁcacy study
All eight pigs in group A-UV developed generalized disease
between 2 and 5 dpc with lesions on all four feet, snout, lower lip
and tongue. In total ﬁve out of eight pigs had temperatures ≥40 ◦C
between 3 and 5 dpc on one or more days. Pig #5, which had lesions
at all sites, had an elevated temperature also at 8 dpc (Table 1).
In group A-V4, none of the eight pigs showed generalized disease
with secondary lesions or increased temperatures, but four of the
pigs developed vesicles at the site of inoculation between 2 and 5
dpc (Table 1).
Two  of the pigs in group A-V7 (#29 and #31) developed vesicles
at the site of inoculation while pigs #28 and #29 showed secondary
lesions on the coronary band of the inoculated feet 7 and 5 dpc,
respectively (Table 1). No other lesions were detected. None of the
contact pigs (groups A-UVC, A-UVC4 and A-UVC7) developed any
lesions or elevated temperatures (data not shown).
3.3. Detection of viral RNA in swabsAll eight pigs in group A-UV had viral RNA in nasal and saliva
swabs by 2 dpc that was  detected in most pigs up to 5 dpc (Table 2;
Supplementary Tables 1 and 2). By 6 dpc, only four pigs tested
act groups did not show any signs of clinical disease or temperature.
5 dpc 6 dpc 7 dpc 8 dpc 9–13 dpc 14 dpca
6 – – – – –
4 – – – – –
4 – – – – –
2 – – – – –
6 – – – – –
6 – – – – –
6 6 6 – – –
2 4 4 – – –
  – – – –
 – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
– – 1 1 – –
 1 – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
 foot (lesion at the site of inoculation was  not counted), tongue, mouth and snout.
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Table 2
Viral RNA detected in nasal, saliva and faecal swabs as well as EDTA blood using RT-qPCR.
Days post challenge
Groups Pig ID 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
A-UV 1 – – SP SP,NP SP,NP SP,NP NP – – – – – – – –
2  – – SP,NP SP,NP SP – – – – – – – – – –
3  – – NP,FP SP,NP SP SP – – – NP – – – – –
4  – – SP,NP,FP SP,NP SP,NP NP – – – – – – – – –
5  – – SP,NP SP,NP NP NP – – – – – – – – –
6  – – SP,NP SP,NP SP SP SP – – NP – – – – –
7  – – SP – SP SP,NP NP – – – – – – – –
8  – – NP – SP,NP SP SP – SP,FP NP – – – – –
A-UVC  9 – – – – – – – – – – – – – – –
10  – – – – – – – – – – – – – – –
11  – – – – – – – – – – – – – – –
12  – – – – – – – – – – – – – – –
13  – – – – – – – – – – – – – – –
A-V4  14 – – – – – – – – – – – – – – –
15  – – – – – – – – – – – – – – –
16  – – – SP – – – – – – – – – – –
17  – – – – – – – – – – – – – – –
18  – – – – – – – – – – – – – – –
19  – – – – NP – – – – – – – – – –
20  – – – – – – – SP – – – – – – –
21  – – – NP – – – – – – – – – – –
A-UVC4 22 – – – NP – – – – NP – – – – – –
23  – – – – NP NP – – – – – – – –
24  – – – NP NP – – NP NP – – – – – –
25  – – – NP – – – – – – NP – – – –
26  – – – – NP NP – – – – – – – – –
A-V7  27 – – – SP,NP SP,FP SP,NP NP – NP – – – – – –
28  – – – SP,NP,FP NP – – – NP – – – – – –
29  – – – SP,NP – SP – – – – – – – – –
30  – – – SP,NP,FP SP,FP SP – – – – – – – – –
31  – – – SP,NP SP SP – SP – – – – – – –
32  – – – SP,NP SP SP,NP – SP – – – – – – –
33  – – – SP,FP – SP,FP – – – – – – – – –
34  – – – NP SP SP – NP – – – – – – –
A-UVC7 35 – – – – – – – – – – – – – – –
36  – – – – – – – – – – – – – – –
37  – – – – – – – – – – – – – – –
38  – – – – – – – – – – – – – – –
39  – – – – – – – – – – – – – – –
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AP—saliva swab positive by PCR, NP—nasal swab positive by PCR, FP—faecal swab p
haded boxes indicate viral RNA detected in blood (animals in groups A-UV, A-V4
-UVC7 were tested on 1, 3, 5, 7, 9, 10 and 14 dpc). The actual values are indicated 
ositive with three of the nasal swabs positive at 9 dpc. In con-
rast, viral RNA was only detected in faecal swabs in three samples
in two pigs at 2 dpc and in one pig at 8 dpc; Table 2; Supplemen-
ary Table 3). No RNA was found in samples collected from pigs in
roup A-UVC.
In group A-V4, four of the eight pigs had positive samples: one
asal and one saliva sample tested positive at 3 dpc, followed by
nother nasal swab at 4 dpc and, ﬁnally, a saliva sample at 7 dpc.
o RNA was detected in the faecal swabs. In contrast, RNA was
etected in only the nasal swabs of all ﬁve indirect contact pigs
group A-UVC4) between 3 and 10 dpc (Table 2; Supplementary
able 1).
Viral RNA was present in all pigs of group A-V7 at 3 dpc, and two
igs had RNA in their nasal swabs at 8 dpc. Four pigs had low levels
f viral RNA in their faecal swabs 3–5 dpc (Table 2, Supplementary
ables 1–3). All swabs collected from the contact pigs in group A-
VC7 were negative..4. Detection of viral RNA in the blood
Viral RNA was detected only in pigs of groups A-UV and
-V7 (Table 2; Supplementary Table 4). In seven of the eight by PCR.
-V7 were tested on 0-7, 9, 10 and 14 dpc; animals in groups A-UVC, A-UVC4 and
plementary Tables 1–4).
unvaccinated and infected pigs (A-UV), RNA was detected between
2 and 10 dpc, while pig #1 tested negative, although it had clinical
disease (Table 1). In group A-V7 viral RNA was detected in six of the
pigs between 1 and 10 dpc with only two  animals having a number
of consecutive days positive. The infected pigs in group A-V4 and
those in contact groups A-UVC, A-UVC4 and A-UVC7 did not have
detectable RNA in the blood.
3.5. Serological response in the study animals
All the pigs were sero-negative on the day of challenge as deter-
mined by the LPBE except three of the eight animals that were
vaccinated seven days prior to challenge (Group A-V7; Fig. 1). By 5
dpc, seven of the unvaccinated pigs had antibodies, ﬁve of the pigs
in group A-V4 and all eight in group A-V7. All the infected animals
were positive by 10 dpc. The indirect contact animals did not have
any detectable antibodies (results not shown).
None of the pigs had antibodies to the non-structural proteins
using the c-ELISA until 7 dpc when ﬁve of the pigs in group A-UV and
one in A-V4 sero-converted (Fig. 1). By 14 dpc six of those in group
A-UV were sero-positive, and two  more in A-V4 demonstrated anti-
bodies as well as one in group A-V7.
S.B. Nagendrakumar et al. / Vaccine 33 (2015) 4513–4519 4517
Fig. 1. Serological results showing the antibody titres determined by LPBE for pigs that were (a) unvaccinated and challenged (A-UV); (b) vaccinated and challenged 4 dpv
(A-V4); and (c) vaccinated and challenged 7 dpv (A-V7). The broken line indicates the cut-off value for declaring positive samples according to the guidelines in the OIE
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.6. Comparison of the amount of viral RNA in various excretions
Pigs in group A-UV had signiﬁcantly more virus than all other
roups in nasal (p <0.05) and saliva (p < 0.05) swabs. Viral RNA in
lood was infrequently identiﬁed, but group A-UV had signiﬁcantly
ore compared to A-V4 (p < 0.05). Group A-V7 also had signiﬁ-
antly more RNA in the blood compared to all groups, except A-UV
p < 0.05). There were no signiﬁcant differences among groups in
he amount of viral RNA detected in faecal samples. Group A-UV
ad signiﬁcantly more RNA compared to the other groups when
valuated over all specimen types (Table 3). Faecal samples had sig-
iﬁcantly less viral RNA compared to saliva and nasal swabs when
valuated over all groups.
. Discussion
In the present study, a >6 PD50/dose A/MAY/97 vaccine was used
o determine its protective ability in pigs 4 and 7 dpv against the
ariant A SEA-97 strain, A/VIT/08/2005. Vaccine efﬁcacy against
his variant virus had not been tested previously. Generalisation
o other sites, such as the uninoculated feet, or mouth, was not
bserved in any of the vaccinated pigs, indicating that the vaccine
rotected against clinical disease. Two of the pigs vaccinated 7 days
rior to infection had lesions on the coronary band of the inoculated
eet at 5 and 7 dpc, respectively, but no other lesions were noted.
he convention when reading protection during vaccine challenge
tudies is to only score lesions on un-inoculated feet, or the mouth.
herefore, it is uncertain whether the lesions on the coronary band,
way from the inoculation site, represented generalised disease.
nly one of these pigs (#29) had viral RNA in the blood. The clinical
cores for both these two pigs were 1, compared to the unvacci-
ated and challenged pigs where the scores ranged from 2 to 6. Six
f the pigs in group A-V7 had viral RNA in the blood. Three of theC7. Stars indicate animals that that had antibodies to the non-structural proteins.
pigs only had detectable RNA in the blood at 5–7 dpc, suggesting
infection by cohorts, rather than by direct inoculation. None of the
pigs vaccinated four days prior to challenge had any viral RNA in
the blood.
Only three of the pigs vaccinated seven days prior to challenge
had detectable antibodies using the LPBE at the time of challenge.
All the other pigs were sero-negative. Protection has been observed
in other cases with low or undetectable antibody levels [21–24].
Barnett et al. [22] argued that in the absence of speciﬁc antibod-
ies, innate immune responses could be the ﬁrst line of defence
against viral intrusion since the majority of viral infections pref-
erentially induce the production of Type 1 interferons. However,
there is also evidence that the swine innate response is inhibited
by FMDV infection [25–27]. This study did not investigate the role of
innate and early adaptive immune responses post vaccination and
infection, but these could explain why  pigs that were vaccinated
four days prior to challenge were protected in the absence of anti-
bodies [23,28,29]. Guzman et al. [30] suggested that such animals
may  be protected because of cell-mediated immune responses. Lev-
els of several cytokines (IL-6, IL-8 and occasionally IL-12) increase
soon after a single application of a high potency vaccine in pigs
[31,28] and some evidence exists that IL-6 might increase the odds
of protection against challenge [32]. In addition, it was previously
shown that IgM peaked in vaccinated pigs by 7 dpv [33], and it is
therefore possible that the protection we observed could in part
have been contributed to this low speciﬁcity and high avidity arm
of the adaptive immune response.
High levels of virus excretion in unvaccinated pigs infected
by intra-dermal injection with a high challenge dose, causing
severe clinical signs, are common in challenge infections in pigs
[34]. Whereas pigs vaccinated with a regular vaccine (3 g/dose
payload of O Taiwan 146S antigen) were protected by 14 dpv
[35]. In our study there was no clinical or serological evidence to
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Table 3
Multivariable model results evaluating the effect of treatment group on the quantity of viral RNA recovered from whole blood and saliva, nasal, and faecal swabs.
Variable Estimate (95% CI) t statistic P value
Experimental group <0.001*
Contact with unvaccinated (A-UVC) −1.41 (−1.70, −1.11) −9.401 <0.001
Contact with vaccinated after 4 days (A-UVC4) −1.23 (−1.53, −0.94) −8.238 <0.001
Contact with vaccinated after 7 days (A-UVC7) −1.41 (−1.70, −1.11) −9.401 <0.001
Vaccinated 4 days prior to exposure (A-V4) −1.40 (−1.65, −1.15) −10.934 <0.001
Vaccinated 7 days prior to exposure (A-V7) −0.59 (−0.84, −0.34) −4.622 <0.001
Unvaccinated exposed (A-UV) Referent
Sample type <0.001*
Nasal swab −0.05 (−0.31, 0.21) −0.378 0.706
Saliva swab 0.07 (−0.19, 0.33) 0.528 0.598
Faecal swab −0.54 (−0.80, −0.28) −4.129 <0.001
Whole blood Referent
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* Overall test for a difference among all treatment groups. Other P values represe
uggest that transmission occurred between the infected pigs and
he unvaccinated indirect contact pigs in the same room. The chal-
enged animals in groups A-UV, A-V4 and A-V7 were excreting
iral RNA, but at signiﬁcantly different levels (P < 0.05) between
 and 9 dpc. No detectable RNA could be found in pigs of groups
-UVC or A-UVC7. On only four occasions were low levels of RNA
ound in oral and nasal swabs of group A-V4 between 3 and 7 dpc,
hile all ﬁve contact pigs had very low levels of RNA in their nasal
wabs between 3 and 10 dpc in the absence of clinical disease or
ero-conversion (Supplementary Table 1). This could indicate that
he pigs were inhaling virus, but not sufﬁcient quantities to cause
nfection.
Pigs are known to be refractory to infection via the respiratory
oute and an infectious aerosol dose of 2,500 TCID50 is required to
stablish disease in close to 100% of experimentally infected pigs
36]. Recently, Gonzales [37] concluded that an infectious aerosol
ose of 3300 and 3900 TCID50 is needed to establish infection
nd disease, respectively, in pigs. Transmission is therefore not
xpected to occur if physical barriers are used to prevent infected
igs from making direct contact with susceptible pigs, and if mea-
ures are taken to prevent the mechanical transfer of virus [36].
n our study, vaccinated pigs excreted 100-fold less viral RNA for
 short duration (3–6 dpc) when compared to the unvaccinated
igs (2–9 dpc), and there was no transmission to the indirect con-
act pigs, probably because of the physical separation and strict
iosecurity measures regarding personnel movements and fomite
ransmission. Similar observations were made with pigs that were
accinated with O1 Manisa vaccine and challenged with an O Mya-
8 lineage virus, where vaccinated animals did not transmit disease
o neighbouring pigs despite RNA being detected in the oral and
asal swabs of the in-contact pigs [38]. Eble et al. [39] also found
hat separation of pigs lowered the transmission rate. This clearly
hows that vaccination, along with efﬁcient biosecurity measures,
hould prevent transmission of FMD  between pens if the animals
re not in direct contact.
The results of the statistical model suggested that the amount
f viral RNA detected in all in-contact groups was  independent of
accination status. However, vaccination was effective at reducing
he amount of viral RNA detected relative to unvaccinated controls.
herefore, this is further evidence that the aerosol route of infec-
ion might not be important for FMDV spreading among pigs. The
odel also suggested that the amount of viral RNA shedding in
-V4 was signiﬁcantly less than A-V7 (based on non-overlapping
5% conﬁdence intervals). The reasons for this observation are dif-
cult to explain and might have been due to individual variability
mong the susceptibility of pigs, challenge dose administration,
r vaccination. This relative effect was observed in all specimen
ypes suggesting that data management or laboratory errors were
nlikely the reason for this ﬁnding. The statistical model also comparison of individual groups to the referent.
suggested that whole blood, oral swabs and nasal swabs con-
tained similar levels of viral RNA, which was higher than what
was detected in faecal swabs. All specimen types, other than faecal
swabs, would therefore appear to be suitable for monitoring the
infection status of pigs.
Extrapolation of experimental results to the ﬁeld is always dif-
ﬁcult and the efﬁcacy of a given vaccine may  differ from what
is observed experimentally [40]. Considering this, when used in
conjunction with biosecurity and movement restrictions, a single
vaccination with A/MAY/97 may  be effective under ﬁeld condi-
tions in pigs challenged with the A SEA-97 lineage to lower virus
excretion and assist in eradication of the virus.
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